|
|
News Breaks | | | | February 5, 2013 | | 05:55 EDT |  | PFE, PFE, PFE, JNJ, JNJ, JNJ, SNY, SNY, SNY, AMGN, AMGN, AMGN, OREX, OREX, OREX, SGEN, SGEN, SGEN, SHPG, SHPG, SHPG, AGN, AGN, AGN, MRK, MRK, MRK, INFI, INFI, INFI, VPHM, VPHM, VPHM, NVO, NVO, NVO | Cambridge Healthtech Institute to host a summit
4th Annual Summit for Clinical Ops Executives: SCOPE to be held in Miami on February 5-7. | |
|
News For NVO;VPHM;INFI;MRK;AGN;SHPG;SGEN;OREX;AMGN;SNY;JNJ;PFE From The Last 14 Days Check below for free stories on NVO;VPHM;INFI;MRK;AGN;SHPG;SGEN;OREX;AMGN;SNY;JNJ;PFE the last two weeks. |
|
|
| June 19, 2013 | | 16:01 EDT |  | PFE | Options Update; June 19, 2013
 Subscribe for More Information | | | 13:53 EDT | | SNY | Sanofi to hold a conference call
Subscribe for More Information | | | 13:50 EDT |  | JNJ | J&J issued FDA warning letter on Xarelto advertising
Subscribe for More Information | | | 12:22 EDT |  | OREX | Outlook for obesity drug coverage has improved, says Leerink
Leerink notes that the VA started covering Vivus' (VVUS) Qsymia in April, while a bipartisan group of lawmakers will introduce a bill today to make Medicare begin covering weight-loss drugs. Meanwhile the AMA has labeled obesity a disease for the first time, Leerink added. The firm believes that the community will begin treating obesity as a disease, and it thinks that recent events could enable weight loss drug makers to exceed its estimates. The firm reiterates Outperform ratings on weight loss drug makers Vivus, Arena (ARNA), and Orexigen (OREX). | | | 10:30 EDT | | PFE | Pfizer management to meet with ISI Group
Subscribe for More Information | | | 10:01 EDT |  | NVO | On The Fly: Analyst Downgrade Summary
Subscribe for More Information | | | 09:49 EDT | | OREX | Weight loss drug makers rise after AMA calls obesity a disease
Makers of anti-obesity drugs are advancing after the American Medical Association designated obesity as a disease. WHAT'S NEW: The AMA recognized obesity as a disease yesterday. Obesity "requires a range of medical interventions," and the treatment and prevention of the condition must be advanced, the organization stated. The AMA's decision will help change the way doctors deal with obesity, AMA board member Patrice Harris, M.D, stated. TODAY'S PRICE ACTION: In early trading, Arena Pharmaceuticals (ARNA) rose 2% to $7.65, while VIVUS (VVUS) climbed 2.4% to $14.10 and Orexigen (OREX) inched up 0.3% to $6.40. | | | 09:38 EDT | | MRK | Active equity option families trading on open
Active equity option families trading on open according to Track Data: AAPL AMAT FDX MA C GOOG DISH AMRN MRK BIDU | | | 09:05 EDT | | SGEN | Seattle Genetics, Takeda announce data from analysis of PFS with ADCETRIS
Takeda Pharmaceutical and Seattle Genetics announced data from a post-hoc analysis examining progression-free survival, PFS, following treatment with ADCETRIS versus last prior therapy in patients diagnosed with relapsed or refractory Hodgkin lymphoma post-autologous stem cell transplant or relapsed or refractory systemic anaplastic large cell lymphoma. The data were highlighted during a presentation at the 12th International Conference on Malignant Lymphoma being held June 19–22, 2013 in Lugano, Switzerland. The post-hoc analysis compared investigator assessed PFS following ADCETRIS single-agent treatment to the last prior systemic therapy in patients taking part in two pivotal Phase 2 studies. “These encouraging data suggest that ADCETRIS may delay disease progression compared to prior therapies used in this heavily pretreated patient population,” said John Radford, M.D., Professor of Medical Oncology, University of Manchester, Manchester, UK. “ADCETRIS is a CD30-targeted treatment option for patients with relapsed or refractory HL or relapsed or refractory sALCL that has shown a high overall response rate, including durable complete responses in both of its approved indications.” | | | 08:45 EDT | | JNJ | Leerink's biotech analyst holds analyst/industry conference call on ADA
Analyst Antlaffy, along with Dr. George Grunberger, founder & Chairman of the Grunberger Diabetes Institute, preview the upcoming American Diabetes Association's conference, including perspectives on new devices in diabetes, potential disruptive technologies at ADA and progress towards the artificial pancreas on an Analyst/Industry conference call to be held on June 20 at 2 pm. | | | | 07:41 EDT | | PFE | Pfizer holders should consider Zoetis exchange, says BMO Capital
BMO Capital thinks Pfizer (PFE) investors should consider participating in the Zoetis (ZTS) exchange as they have the opportunity to own Zoetis at around $29.40-$29.70 per share, which is 15% below BMO's valuation of $34 per share. Further, BMO thinks there is strong support for Zoetis below $30, which the firm feels lowers downside risk. BMO recommends that Pfizer investors tender around 20% of their shares into the exchange, noting that with the offer likely being oversubscribed, not all tendered shares will be converted to Zoetis. | | | 06:52 EDT |  | OREX | AMA recognizes obesity as disease. NY Times reports
The American Medical Association, or AMA, has officially recognized obesity as a disease, The New York Times reported yesterday. The decision could cause more insurance companies to pay for obesity treatments and spur more doctors to take more steps to combat the condition, the newspaper stated. The AMA overrode a recommendation by a committee that had recommended against making the change, the newspaper noted. Reference Link | | | 05:44 EDT | | NVO | Novo Nordisk downgraded to Underperform from Neutral at Exane BNP Paribas
Subscribe for More Information | | | June 18, 2013 | | 19:07 EDT | | AMGN | On The Fly: After Hours Movers
Subscribe for More Information | | | 17:25 EDT | | AMGN | Amgen reports 7.58% stake in Cytokinetics
Subscribe for More Information | | | 16:00 EDT | | MRK | Options Update; June 18, 2013
Subscribe for More Information | | | 15:15 EDT | | NVO | Novo Nordisk says court rules against company in patent litigation
Subscribe for More Information | | | 11:20 EDT | | INFI | Infinity Pharmaceuticals shares up 11%, or $1.97, to $19.14
Subscribe for More Information | | | 09:38 EDT | | PFE | Active equity option families trading on open
Active equity option families trading on open according to Track Data: AAPL NFLX GOOG PFE TSLA MGM | | | 09:04 EDT | | AGN | Wells Faro to host a conference
2013 Healthcare Conference is being held in Boston on June 18-19 with webcasted company presentations to begin at 8:15 am; not all company presentations may be webcasted. Webcast Link | | |
|
|
|
|
|
|
